AstraZeneca acquires TeneoTwo in $1.3bn deal to broaden haematology portfolio
Pharmaceutical Technology
JULY 8, 2022
Moreover, a deeper understanding of immune evasion by cancer cells may provide novel sensitization strategies to further enhance the clinical response of BiTEs. . The confirmatory Phase III TOWER trial demonstrated superior overall survival in R/R B-ALL patients with Blincyto versus conventional chemotherapy (7.7 months vs. 4.0
Let's personalize your content